PP405 / Pelage Pharma - LARVOL DELTA

AWAKEN: Phase 2/3 Efficacy and Safety of PP405 in Adult Males (clinicaltrials.gov) - P2/3 | N=600 | Not yet recruiting | Sponsor: Pelage Pharmaceuticals, Inc.

New P2/3 trial • Alopecia • Dermatology • Immunology

Emerging pharmacotherapies for Androgenetic Alopecia. (PubMed, Expert Opin Pharmacother) - "These include topical androgen-receptor antagonists and degraders (clascoterone, GT20029), biologics targeting prolactin receptor inhibition (HMI-115, ABS-201), anagen-inducing injectables (AMP-303), metabolic and follicular activators (PP405, ET-02), thyroid hormone receptor-β agonists (KB-141), optimized potassium channel opener delivery systems (extended-release and sublingual minoxidil) and modulation of longevity pathways using rapamycin and metformin. Collectively, these newer pharmacotherapeutics aim to improve efficacy, safety, and patient adherence. Ongoing and future clinical trials will determine their definitive role in reshaping the therapeutic landscape of androgenetic alopecia."

Journal • Review • Alopecia • Immunology

Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA (clinicaltrials.gov) - P2 | N=78 | Completed | Sponsor: Pelage Pharmaceuticals, Inc. | Active, not recruiting ➔ Completed | Trial primary completion date: Nov 2025 ➔ Jul 2025

Trial completion • Trial primary completion date • Alopecia • Dermatology • Immunology

Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA (clinicaltrials.gov) - P2 | N=78 | Active, not recruiting | Sponsor: Pelage Pharmaceuticals, Inc. | N=60 ➔ 78 | Trial completion date: Feb 2025 ➔ Dec 2025 | Trial primary completion date: Dec 2024 ➔ Nov 2025

Enrollment change • Trial completion date • Trial primary completion date • Alopecia • Dermatology • Immunology

Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA (clinicaltrials.gov) - P2 | N=60 | Active, not recruiting | Sponsor: Pelage Pharmaceuticals, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Alopecia • Dermatology • Immunology

Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: Pelage Pharmaceuticals, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Alopecia • Dermatology • Immunology